|Bid||3.6800 x 1100|
|Ask||3.6900 x 900|
|Day's Range||3.4200 - 3.9100|
|52 Week Range||3.1000 - 9.4650|
|Beta (5Y Monthly)||3.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.67|
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Libervant™ NDA resubmission accepted, PDUFA goal date of December 23, 2021On track to report top-line data from Phase 1 study for AQST-109 epinephrine sublingual film in second half 2021Increases full year revenue guidanceHosts conference call at 8:00 a.m. ET on August 4, 2021 WARREN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.